PL3600282T3 - Modulatory receptora glukokortykoidowego w leczeniu nowotworu szyjki macicy - Google Patents

Modulatory receptora glukokortykoidowego w leczeniu nowotworu szyjki macicy

Info

Publication number
PL3600282T3
PL3600282T3 PL18777520.0T PL18777520T PL3600282T3 PL 3600282 T3 PL3600282 T3 PL 3600282T3 PL 18777520 T PL18777520 T PL 18777520T PL 3600282 T3 PL3600282 T3 PL 3600282T3
Authority
PL
Poland
Prior art keywords
treatment
cervical cancer
receptor modulators
glucocorticoid receptor
glucocorticoid
Prior art date
Application number
PL18777520.0T
Other languages
English (en)
Inventor
Hazel Hunt
Original Assignee
Corcept Therapeutics Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corcept Therapeutics Incorporated filed Critical Corcept Therapeutics Incorporated
Publication of PL3600282T3 publication Critical patent/PL3600282T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL18777520.0T 2017-03-31 2018-03-30 Modulatory receptora glukokortykoidowego w leczeniu nowotworu szyjki macicy PL3600282T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762480226P 2017-03-31 2017-03-31
PCT/US2018/025547 WO2018183947A1 (en) 2017-03-31 2018-03-30 Glucocorticoid receptor modulators to treat cervical cancer

Publications (1)

Publication Number Publication Date
PL3600282T3 true PL3600282T3 (pl) 2025-12-15

Family

ID=63671917

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18777520.0T PL3600282T3 (pl) 2017-03-31 2018-03-30 Modulatory receptora glukokortykoidowego w leczeniu nowotworu szyjki macicy

Country Status (20)

Country Link
US (6) US10413540B2 (pl)
EP (1) EP3600282B1 (pl)
JP (3) JP7563882B2 (pl)
KR (1) KR102342620B1 (pl)
CN (1) CN110520121B (pl)
AU (1) AU2018244928B2 (pl)
CA (1) CA3055076C (pl)
DK (1) DK3600282T3 (pl)
ES (1) ES3052720T3 (pl)
FI (1) FI3600282T3 (pl)
IL (1) IL269725B (pl)
MX (1) MX2019011543A (pl)
PH (1) PH12019502259A1 (pl)
PL (1) PL3600282T3 (pl)
PT (1) PT3600282T (pl)
RU (1) RU2019129299A (pl)
SG (1) SG11201908790PA (pl)
UA (1) UA127409C2 (pl)
WO (1) WO2018183947A1 (pl)
ZA (1) ZA201905736B (pl)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8859774B2 (en) * 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
US12226412B2 (en) 2012-05-25 2025-02-18 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
FI3600282T3 (fi) * 2017-03-31 2025-11-07 Corcept Therapeutics Inc Glukokortikoidireseptorien modulaattoreita kohdunkaulan syövän hoitoon
CN111202849B (zh) * 2018-11-02 2022-06-03 四川大学 一种白蛋白结合型亚硝基脲类抗肿瘤药物制剂及其制备方法
US11234971B2 (en) 2018-12-19 2022-02-01 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
CA3121193C (en) 2018-12-19 2024-03-12 Corcept Therapeutics Incorporated Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound
US11389432B2 (en) 2018-12-19 2022-07-19 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
ES2980934T3 (es) 2019-01-22 2024-10-03 Akribes Biomedical Gmbh Modificadores selectivos del receptor de glucocorticoides para tratar la cicatrización alterada de heridas en la piel
WO2020172501A1 (en) 2019-02-22 2020-08-27 Corcept Therapeutics Incorporated Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator
US12440487B2 (en) 2019-10-16 2025-10-14 Corcept Therapeutics Incorporated Method of normalizing the neutrophil to lymphocyte ratio in cancer patients with a selective glucocorticoid receptor antagonist
EP4103180A4 (en) * 2020-02-10 2024-03-13 Corcept Therapeutics Incorporated METHOD FOR STIMULATING AN ANTI-TUMOR RESPONSE USING A SELECTIVE GLUCOCORTICOID RECEPTOR MODULATOR
CA3178756A1 (en) * 2020-05-27 2021-12-02 Hazel Hunt Concomitant administration of glucocorticoid receptor modulator relacorilant and paclitaxel, a dual substrate of cyp2c8 and cyp3a4
EP4157274A4 (en) * 2020-05-27 2024-06-12 Corcept Therapeutics Incorporated CONCURRENT ADMINISTRATION OF GLUCOCORTICOID RECEPTOR MODULATOR RELACTORILANTS AND CYP2C9 SUBSTRATES
CA3178767A1 (en) * 2020-05-27 2021-12-02 Hazel Hunt Concomitant administration of glucocorticoid receptor modulator relacorilant and cyp2c8 substrates
WO2022134033A1 (en) 2020-12-25 2022-06-30 Corcept Therapeutics Incorporated Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
CA3265456A1 (en) * 2022-09-02 2024-03-07 Corcept Therapeutics Incorporated METHODS FOR EVALUATING THE SELECTIVE MODULATION OF GLUCOCORTICOID RECEPTORS AND FOR IDENTIFYING AND TREATMENT OF PATIENTS LIKELY TO BENEFIT FROM GLUCOCORTICOID RECEPTOR MODULATION
KR20250073629A (ko) 2022-10-06 2025-05-27 코어셉트 쎄라퓨틱스 인코포레이티드 글루코코르티코이드 수용체 조절제의 제형
EP4608402A1 (en) 2022-10-28 2025-09-03 Corcept Therapeutics Incorporated Treatments for amyotrophic lateral sclerosis using dazucorilant

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4391904A (en) 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
US4296206A (en) 1980-04-30 1981-10-20 United States Of America Irreversible anti-glucocorticoids
FR2528434B1 (fr) 1982-06-11 1985-07-19 Roussel Uclaf Nouveaux 19-nor steroides substitues en 11b et eventuellement en 2, leur procede de preparation et leur application comme medicament
US4978657A (en) 1981-01-09 1990-12-18 Roussel Uclaf Novel 11β-substituted-19-nor-steroids
ZA8231B (en) 1981-01-09 1982-11-24 Roussel Uclaf New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained
FR2639045B2 (fr) 1982-03-01 1994-07-29 Roussel Uclaf Nouveaux produits derives de la structure 3-ceto-delta-4,9-19-nor steroides et leur application comme medicaments
FR2522328B1 (fr) 1982-03-01 1986-02-14 Roussel Uclaf Nouveaux produits derives de la structure 3-ceto 4,9 19-nor steroides, leur procede de preparation et leur application comme medicaments
IL72729A (en) 1983-09-26 1988-02-29 Lilly Co Eli Trans(+_)octahydropyrazole-ring alkylated pyrazoloquinolines,their preparation and pharmaceutical compositions containing them
DE3438994A1 (de) 1984-10-22 1986-04-24 Schering AG, Berlin und Bergkamen, 1000 Berlin Antigestagene, glukokortikoide und prostaglandine zur geburtseinleitung oder fuer den schwangerschaftsabbruch
FR2576025B1 (fr) 1985-01-14 1987-01-23 Roussel Uclaf Nouveaux steroides substitues en position 10, leur procede et les intermediaires de preparation, leur application comme medicaments, les compositions pharmaceutiques les contenant
NZ214998A (en) 1985-02-07 1989-06-28 Schering Ag 13-(methyl or ethyl)-11-beta-phenyl-gonane derivatives; preparatory processes and pharmaceutical compositions
DE3506785A1 (de) 1985-02-22 1986-08-28 Schering AG, Berlin und Bergkamen, 1000 Berlin 11ss-n,n-dimethylaminophenyl-estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate
US5380839A (en) 1985-09-12 1995-01-10 The Upjohn Company Phenylpiperazinyl steroids
FR2598421B1 (fr) 1986-05-06 1988-08-19 Roussel Uclaf Nouveaux produits 19-nor ou 19-nor d-homo steroides substitues en position 11b par un radical phenyle portant un radical alkynyle, leur procede de preparation, leur application comme medicaments et les compositions les renfermant
EP0254341B1 (en) 1986-07-23 1990-01-03 Akzo N.V. Novel 18-phenyloestrane derivatives
DE3625315A1 (de) 1986-07-25 1988-01-28 Schering Ag 11ss-(4-isopropenylphenyl)-estra-4,9-diene, deren herstellung und diese enthaltende pharmazeutische praeparate
US4861763A (en) 1986-09-17 1989-08-29 Research Triangle Institute 17 α-(substituted-methyl)-17β-hydroxy/esterified hydroxy steroids and their progestational use
US4774236A (en) 1986-09-17 1988-09-27 Research Triangle Institute 17α-(substituted-methyl)-17β-hydroxy/esterified hydroxy steroids and pharmaceutical compositions containing them
US5071773A (en) 1986-10-24 1991-12-10 The Salk Institute For Biological Studies Hormone receptor-related bioassays
US4921638A (en) 1986-11-05 1990-05-01 The Upjohn Company 17β-cyano-9α,17α-dihydroxyandrost-4-en-3-one
DE3708942A1 (de) 1987-03-18 1988-09-29 Schering Ag 19,11ss-ueberbrueckte steroide, deren herstellung und diese enthaltende pharmazeutische praeparate
DE3723788A1 (de) 1987-07-16 1989-01-26 Schering Ag 11(beta)-phenyl-4,9,15-estratriene, deren herstellung und diese enthaltende pharmazeutische praeparate
FR2618783B1 (fr) 1987-07-30 1991-02-01 Roussel Uclaf Nouveaux 17-aryle steroides, leurs procedes et des intermediaires de preparation comme medicaments et les compositions pharmaceutiques les renfermant
JP2785023B2 (ja) 1987-12-30 1998-08-13 ルセル―ユクラフ １７α位置を置換された１７β―ＯＨ―１９―ノルステロイドの新誘導体、その製造方法、その薬剤としての使用及びそれを含有する製薬組成物
DE3820948A1 (de) 1988-06-16 1989-12-21 Schering Ag 10ss, 11ss-ueberbrueckte steroide
US4954490A (en) 1988-06-23 1990-09-04 Research Triangle Institute 11 β-substituted progesterone analogs
US5348729A (en) 1988-11-30 1994-09-20 The United States Of America As Represented By The Department Of Health And Human Services Evaluative means for detecting inflammatory reactivity
GB8828669D0 (en) 1988-12-08 1989-01-11 Lilly Industries Ltd Organic compounds
DD289541A5 (de) 1989-08-04 1991-05-02 ��@�K@�������������@�K@��������������@��������k�� Verfahren zur herstellung von 11beta-aryl-16 alpha, 17 alph-cyclohexanoestra-4,9-dienen
US5276023A (en) 1989-08-08 1994-01-04 Roussel Uclaf 19-nor-steroid esters
FR2651233B1 (fr) 1989-08-23 1991-12-13 Roussel Uclaf Nouveaux acides omega-phenylamino alcanouiques substitues sur le noyau aromatique par un radical derive de 19-norsterouides, leur procede de preparation, leur application a titre de medicaments et les compositions les renfermant.
US5173405A (en) 1990-01-23 1992-12-22 The United States Of America As Represented By The Department Of Health And Human Services Use of arsenite to reversibly block steroid binding to glucocorticoid receptors in the presence of other steroid receptors
US5616458A (en) 1990-03-14 1997-04-01 Board Of Regents, University Of Tx System Tripterygium wilfordii hook F extracts and components, and uses thereof
DE4042004A1 (de) 1990-12-22 1992-06-25 Schering Ag 14(beta)-h-, 14- u. 15-en-11(beta)-aryl-4-estrene
US5215916A (en) 1991-06-19 1993-06-01 The United States Of America As Represented By The Department Of Health & Human Services Super glucocorticoid receptors: receptors with increased affinity and specificity for glucocorticoid steriods
US5439913A (en) 1992-05-12 1995-08-08 Schering Aktiengesellschaft Contraception method using competitive progesterone antagonists and novel compounds useful therein
CN1043641C (zh) 1993-08-06 1999-06-16 史密丝克莱恩比彻姆制药股份公司 氢化异喹啉衍生物
US6051573A (en) 1994-06-28 2000-04-18 Alcon Laboratories, Inc. Treatment of GLC1A glaucoma with non-steroidal glucocorticoid antagonists
JPH10510840A (ja) 1994-12-22 1998-10-20 リガンド・ファーマシューティカルズ・インコーポレイテッド ステロイド受容体モジュレーター化合物および方法
US5696133A (en) 1994-12-22 1997-12-09 Ligand Pharmaceuticals Incorporated Steroid receptor modulator compounds and methods
AU5729098A (en) 1996-12-24 1998-07-17 Zymogenetics Inc. Treatment agents and methods for treating type ii diabetes and symptoms of type ii diabetes
JP4498602B2 (ja) 1998-03-10 2010-07-07 リサーチ・トライアングル・インスティチュート 新規なオピエート化合物、その調製法及び使用法
GB9911053D0 (en) 1999-05-12 1999-07-14 Pharmacia & Upjohn Spa 4,5,6,7-tetrahydroindazole derivatives process for their preparation and their use as antitumour agents
GB0010683D0 (en) 2000-05-03 2000-06-28 Univ Bristol Cancer therapy
DE10038639A1 (de) 2000-07-28 2002-02-21 Schering Ag Nichtsteroidale Entzündungshemmer
IL180679A0 (en) 2000-10-27 2009-02-11 Pfizer Prod Inc Process for the preparation of non-steroidal glucocorticoid receptor modulators
US6583180B2 (en) 2001-02-14 2003-06-24 Abbott Laboratories Glucocorticoid receptor modulators
WO2002069995A2 (en) 2001-02-16 2002-09-12 Medical College Of Georgia Research Institute, Inc. Use of trail and antiprogestins for treating cancer
WO2003015692A2 (en) 2001-07-17 2003-02-27 Smithkline Beecham Corporation Crystallized glucocorticoid receptor ligand binding domain polypeptide and screening methods employing same
WO2003009853A1 (en) 2001-07-23 2003-02-06 Corcept Therapeutics, Inc. Methods for preventing antipsychotic-induced weight gain
JP4745609B2 (ja) 2002-01-22 2011-08-10 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア グルココルチコイドレセプターのための非ステロイド性リガンド、その組成物および使用
US20030162695A1 (en) 2002-02-27 2003-08-28 Schatzberg Alan F. Glucocorticoid blocking agents for increasing blood-brain barrier permeability
WO2004004653A2 (en) 2002-07-02 2004-01-15 Corcept Therapeutics, Inc. Methods for treating psychosis associated with interferon-alpha therapy
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
CN1874771A (zh) 2003-09-03 2006-12-06 惠氏公司 3－羟基－2－(羟甲基)－2－甲基丙酸的非晶态雷帕霉素42－酯及其包含相同化合物的药用组合物
CA2552419C (en) 2004-01-09 2013-04-23 Corcept Therapeutics, Inc. Azadecalin glucocorticoid receptor modulators
EP1723174A1 (en) 2004-02-26 2006-11-22 The Government of the U.S.A., as repr. by the Secretary, Dept. of Health & Human Services, the Nat. Inst. of Health A novel modulator of glucocorticoid receptor activities
CA2558899C (en) 2004-03-09 2013-02-05 Corcept Therapeutics, Inc. Fused ring azadecalin glucocorticoid receptor modulators
PT1778236E (pt) 2004-07-02 2010-10-19 Corcept Therapeutics Inc Moduladores do receptor de glucocorticóide de pirimidina modificada
DK1888550T3 (da) 2005-05-12 2014-09-29 Abbvie Bahamas Ltd Apoptosepromotorer
US7790745B2 (en) 2005-10-21 2010-09-07 Bristol-Myers Squibb Company Tetrahydroisoquinoline LXR Modulators
US7640389B2 (en) 2006-02-28 2009-12-29 Freescale Semiconductor, Inc. Non-volatile memory having a multiple block erase mode and method therefor
EP1932843A1 (en) 2006-12-14 2008-06-18 sanofi-aventis Sulfonyl-phenyl-2H-(1,2,4) oxadiazole-5-one derivatives, processes for their preparation and their use as pharmaceuticals
AU2008321128A1 (en) 2007-11-12 2009-05-22 Bipar Sciences, Inc. Treatment of breast cancer with a PARP inhibitor alone or in combination with anti-tumor agents
US20120022121A1 (en) 2007-11-29 2012-01-26 Dalton James T Indoles, derivatives and analogs thereof and uses therefor
US20090156672A1 (en) 2007-12-17 2009-06-18 Northwestern University Substituted Phenyl Aziridine Precursor Analogs as Modulators of Steroid Receptor Activities
WO2009155481A1 (en) 2008-06-20 2009-12-23 Gtx, Inc. Metabolites of selective androgen receptor modulators and methods of use thereof
US20100135956A1 (en) 2008-11-21 2010-06-03 Auspex Pharmaceuticals, Inc. Steroid modulators of progesterone receptor and/or glucocorticoid receptor
EP2429529B1 (en) 2009-05-12 2015-01-14 Corcept Therapeutics, Inc. Solid forms and process for preparing
US8710035B2 (en) 2010-03-24 2014-04-29 The University Of Chicago Methods and compositions related to glucocorticoid receptor antagonists and breast cancer
BR112013004322A2 (pt) 2010-08-27 2016-06-21 Corcept Therapeutics Inc moduladores de azadecalin fundidos com piridil-aminas
US8318726B2 (en) * 2010-12-06 2012-11-27 Council Of Scientific & Industrial Research Benzylidineanthracenone linked pyrrolobenzodiazepine hybrids useful as anticancer agents and process for the preparation thereof
US9314473B2 (en) 2011-02-03 2016-04-19 Pop Test Oncology Limited Liability Company System and method for diagnosis and treatment
JP5804395B2 (ja) 2011-02-03 2015-11-04 ポップ テスト オンコロジー エルエルシー 診断と治療のためのシステムおよび方法
ES2563444T3 (es) 2011-03-18 2016-03-15 Corcept Therapeutics, Inc. Moduladores del receptor de glucocorticoide de tipo pirimidina ciclohexilo
WO2013039916A1 (en) 2011-09-12 2013-03-21 The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services Compositions for and methods of treatment and enhanced detection of non-pituitary tumors
TWI582095B (zh) 2011-11-11 2017-05-11 基利阿波羅有限責任公司 Ａｃｃ抑制劑及彼等之用途
US9289436B2 (en) 2012-02-24 2016-03-22 The University Of Chicago Method of treatment of prostate cancer with androgen receptor and glucocorticoid receptor antagonists
WO2013130420A1 (en) 2012-02-27 2013-09-06 Corcept Therapeutics, Inc. Phenyl heterocycloalkyl glucocorticoid receptor modulators
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
SG11201407336PA (en) 2012-05-25 2015-03-30 Janssen Sciences Ireland Uc Uracyl spirooxetane nucleosides
SG11201407682TA (en) 2012-05-25 2014-12-30 Corcept Therapeutics Inc Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
KR101915942B1 (ko) 2012-06-08 2018-11-06 에프. 호프만-라 로슈 아게 암의 치료를 위한 포스포이노시타이드 3 키나제 억제제 화합물 및 화학치료제의 돌연변이체 선택성 및 조합물
EP4219494A1 (en) 2013-11-25 2023-08-02 Corcept Therapeutics Incorporated Octahydro fused azadecalin glucocorticoid receptor modulators
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
EP3006453A1 (en) 2014-10-08 2016-04-13 Cosmo Technologies Ltd. 17alpha-monoesters and 17alpha,21-diesters of cortexolone for use in the treatment of tumors
US10047157B2 (en) 2014-12-19 2018-08-14 Alder Biopharmaceuticals, Inc. Humanized anti-ACTH antibodies and use thereof
WO2016141365A1 (en) * 2015-03-05 2016-09-09 Abraxis Bioscience, Llc Method for treating cancer based on level of glucocorticoid receptor
CA2978960C (en) 2015-03-30 2023-05-02 Corcept Therapeutics, Inc. Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency
US9598459B2 (en) * 2015-08-03 2017-03-21 Pop Test Oncology Llc Pharmaceutical compositions and methods
CA2994422A1 (en) 2015-08-13 2017-02-16 Corcept Therapeutics, Inc. Method for differentially diagnosing acth-dependent cushing's syndrome
WO2017127448A1 (en) 2016-01-19 2017-07-27 Corcept Therapeutics, Inc. Differential diagnosis of ectopic cushing's syndrome
PH12018501848B1 (en) * 2016-03-01 2024-02-23 Corcept Therapeutics Inc The use of glucocorticoid receptor modulators to potentiate checkpoint inhibitors
US9943505B2 (en) 2016-09-09 2018-04-17 Corcept Therapeutics, Inc. Glucocorticoid receptor modulators to treat pancreatic cancer
FI3600282T3 (fi) * 2017-03-31 2025-11-07 Corcept Therapeutics Inc Glukokortikoidireseptorien modulaattoreita kohdunkaulan syövän hoitoon
US10780097B2 (en) 2018-07-02 2020-09-22 Corcept Therapeutics, Inc. Use of cortisol in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients
WO2020172501A1 (en) 2019-02-22 2020-08-27 Corcept Therapeutics Incorporated Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator

Also Published As

Publication number Publication date
DK3600282T3 (da) 2025-11-17
MX2019011543A (es) 2019-12-16
SG11201908790PA (en) 2019-10-30
JP2022084888A (ja) 2022-06-07
US20190076424A1 (en) 2019-03-14
RU2019129299A3 (pl) 2021-04-30
RU2019129299A (ru) 2021-04-30
ES3052720T3 (en) 2026-01-13
US20180280378A1 (en) 2018-10-04
CA3055076C (en) 2022-02-22
US12285425B2 (en) 2025-04-29
US20200147073A1 (en) 2020-05-14
KR20190126442A (ko) 2019-11-11
PT3600282T (pt) 2025-11-05
UA127409C2 (uk) 2023-08-16
AU2018244928A1 (en) 2019-09-19
US10413540B2 (en) 2019-09-17
IL269725B (en) 2020-07-30
US20230355610A1 (en) 2023-11-09
US20250295650A1 (en) 2025-09-25
FI3600282T3 (fi) 2025-11-07
JP7563882B2 (ja) 2024-10-08
US10898478B2 (en) 2021-01-26
US10568880B2 (en) 2020-02-25
IL269725A (en) 2019-11-28
US11660295B2 (en) 2023-05-30
WO2018183947A1 (en) 2018-10-04
JP2025063305A (ja) 2025-04-15
KR102342620B1 (ko) 2021-12-22
US20210085670A1 (en) 2021-03-25
EP3600282A4 (en) 2020-08-19
PH12019502259A1 (en) 2020-07-13
ZA201905736B (en) 2022-10-26
NZ756852A (en) 2024-11-29
CA3055076A1 (en) 2018-10-04
CN110520121A (zh) 2019-11-29
AU2018244928B2 (en) 2023-10-19
CN110520121B (zh) 2023-07-04
EP3600282A1 (en) 2020-02-05
EP3600282B1 (en) 2025-09-10
JP2020515563A (ja) 2020-05-28

Similar Documents

Publication Publication Date Title
PL3600282T3 (pl) Modulatory receptora glukokortykoidowego w leczeniu nowotworu szyjki macicy
IL265217A (en) Glucocorticoid receptor modulators to treat pancreatic cancer
IL275600A (en) Exosomes for immuno-oncology and anti-inflammatory therapy
IL271888A (en) Therapeutic and diagnostic methods for cancer
IL269150A (en) Compositions and methods for treating cancer
IL272410A (en) Cytokine conjugates for the treatment of autoimmune diseases
IL268814A (en) Compositions and methods for treatment of cancer
HUE064141T2 (hu) Azolopirimidin rákkal összefüggõ rendellenességek kezelésére
IL258955A (en) Compositions and methods for treatment of cancer
HUE053452T2 (hu) Anti-PD-1 és anti-LAG3 antitestek rák kezelésére
IL270511A (en) Combination therapies using niraparib and pembrolizumab for treating cancer
IL263224A (en) Methods and compositions for treating cancers
HUE054548T2 (hu) Amino-triazolopiridin vegyületek és azok alkalmazása rák kezelésében
DK3658192T3 (da) Glucocorticoid-receptoragonist og immunokonjugater deraf
IL268872A (en) Methods and compositions for treating cancers using antisense
IL272095A (en) 17-alpha-21-cortexolone diesters for use in the treatment of tumors and as glucocorticoid receptor modulators
PL3114145T3 (pl) Przeciwciała przeciw ludzkiemu białku pomocniczemu receptora interleukiny-1 (il1rap) i ich zastosowania
IL257274B (en) Compositions and methods for treating cancers associated with etbr activation
IL269157A (en) Compositions and methods for treating cancer
EP3682022A4 (en) HUMAN THERAPEUTIC TARGET MOLECULES AND MODULATORS THEREOF
PL3490560T3 (pl) Niraparyb do stosowania w sposobie leczenia nowotworu prostaty
EP3548047A4 (en) ADMINISTRATION OF STEROIDS AND IMMUNOTHERAPY
DK3532067T3 (da) Liposomal formulering til anvendelse til behandling af cancer
PL3732294T3 (pl) Tymohydrochinon do stosowania w leczeniu hiperglikemii
IL271327A (en) Compositions and methods for enhancing hyperthermic therapy